Please provide your email address to receive an email when new articles are posted on . Patients with MS had lower corneal nerve fiber density, corneal nerve branch density and corneal nerve fiber ...

Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as "relapsing" or "progressive." An international study, published on August 20, 2025, in Nature Medicine under ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various associated neurological symptoms, ranging from vision problems to numbness, ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

Share on Pinterest Subtle signs of multiple sclerosis may appear more than a decade before onset, recent research suggests. Image credit: Pancake Pictures/Getty Images Research is ongoing regarding ...

FRANKFURT, April 30 (Reuters) - Merck KGaA has started a mid-stage trial to evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis, the German drugs and chemicals ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...

The researchers compared the CD8 T cells of monozygotic twin pairs, of which one twin suffers from MS while the other is asymptomatic and found specific changes These findings could open new ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Oct 10 (Reuters) - Denali Therapeutics (DNLI.O), opens new tab said on Thursday its partner Sanofi (SASY.PA), opens new tab has discontinued a mid-stage study testing their experimental drug to treat ...